Progenics Stock Drops After Study Reveals Two Deaths in Trial

Jan 30, 2014


Progenics Pharmaceuticals Inc., Tarrytown, N.Y., stocks fell nearly 20 percent after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment. The study abstract appears to show that even at a lower dose of the drug, PSMA-ADC, patients could experience life-threatening levels of toxicity, said Brian Klein, an analyst at New York-based Stifel Nicolaus & Co. Read the full story

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments